Charles Jarreau
Acute Care · New Orleans, LANPI 1346563681
Payments from drug & device makers
Across 586 payments — averaging $68.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$18K
- Lilly USA, LLC$13K
- AstraZeneca$2K
- Amgen$2K
- Otsuka America Pharmaceutical, Inc.$838
- Calliditas Therapeutics US Inc.$704
- plus $4K from 27 others
What the payments were for
- Speaking & faculty fees$29,26373%
- Travel & lodging$5281%
- Food & beverage$10,33926%
- Education$1550%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 74 | $18,134 |
| Lilly USA, LLC | 63 | $13,188 |
| AstraZeneca(2 entities) | 90 | $1,757 |
| Amgen(2 entities) | 81 | $1,589 |
| Otsuka America Pharmaceutical, Inc. | 45 | $838 |
| Calliditas Therapeutics US Inc. | 40 | $704 |
| Novo Nordisk | 21 | $486 |
| Fresenius USA Marketing, Inc. | 23 | $466 |
| Mallinckrodt Hospital Products Inc. | 11 | $325 |
| Vifor Pharma, Inc. | 19 | $325 |
| Bayer | 13 | $278 |
| Sanofi-aventis U.S. LLC | 12 | $251 |
| OPKO Pharmaceuticals, LLC | 15 | $230 |
| Akebia Therapeutics Inc | 12 | $229 |
| Novartis | 9 | $213 |
| GSK | 10 | $205 |
| Medtronic | 3 | $187 |
| Travere Therapeutics, Inc. | 8 | $169 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 9 | $146 |
| Aurinia Pharma U.S., Inc. | 6 | $128 |
| Cormedix Inc. | 3 | $72 |
| Xeris Pharmaceuticals, Inc. | 3 | $68 |
| Ardelyx, Inc. | 2 | $48 |
| Merck | 3 | $43 |
| Alnylam Pharmaceuticals Inc. | 2 | $39 |
| Scpharmaceuticals Inc. | 2 | $31 |
| ANI Pharmaceuticals, Inc. | 1 | $27 |
| Recordati_rare_diseases_inc. | 1 | $26 |
| Dexcom, Inc. | 1 | $22 |
| Insulet Corporation | 1 | $18 |
| Esperion Therapeutics, Inc. | 1 | $17 |
| Outset Medical Inc | 1 | $15 |
| Shield Therapeutics Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$30,365
- Ozempic$125
- Repatha$122
- Minimed 670G System$118
How this compares
$40,285 in reported general payments places this provider in the 95th percentile of 248 acute care providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 129 | $172,593 |
| JardianceEmpagliflozin | 149 | $149,988 |
| FarxigaDapagliflozin Propanediol | 110 | $76,888 |
| MounjaroTirzepatide | 40 | $44,076 |
| Tresiba Flextouch U-200Insulin Degludec | 64 | $41,234 |
| Repatha SureclickEvolocumab | 50 | $36,113 |
| EliquisApixaban | 28 | $29,309 |
| ProliaDenosumab | 16 | $27,904 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 33 | $23,256 |
| RybelsusSemaglutide | 23 | $22,619 |
| EntrestoSacubitril/Valsartan | 18 | $20,204 |
| FiaspInsulin Aspart (Niacinamide) | 15 | $19,505 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $14,930 |
| TrulicityDulaglutide | 12 | $10,561 |
| RetacritEpoetin Alfa-Epbx | 11 | $9,558 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Fiasp | $486 | $214,717167 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta | $18,134 | $164,099174 claims |
| AstraZenecaFarxiga, Symbicort | $1,757 | $80,118124 claims |
| Lilly USA, LLCMounjaro, Trulicity | $13,188 | $54,63752 claims |
| AmgenProlia | $1,589 | $27,90416 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $251 | $23,25633 claims |
| NovartisEntresto | $213 | $20,20418 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 248 acute care providers in Louisiana.
Other acute care in New Orleans
- Anita RichardNew Orleans$7K
- Candita ThompsonNew Orleans$2K
- Erica LoveNew Orleans$2K
- Annie StadstadNew Orleans$2K
- Jennifer FlemingNew Orleans$2K
- Travis KingNew Orleans$2K
- Precious HodgesLafayette$70K
- Brinton FegleyShreveport$61K
- Jeremy DavisShreveport$35K
- Heather MecomShreveport$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.